The Analyst Landscape: 4 Takes On Harrow
Portfolio Pulse from Benzinga Insights
Harrow (NASDAQ:HROW) has received varied analyst ratings over the past three months, with a shift towards bullish sentiment. Analysts have raised their price targets, with the current average target at $52.5, up 36.36% from the previous $38.50. Harrow, an eyecare pharmaceutical company, has shown strong revenue growth but faces challenges with its ROE and ROA.
October 04, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow has seen a positive shift in analyst sentiment, with a 36.36% increase in average price target to $52.5. Analysts have raised their ratings, reflecting optimism about the company's future performance. Despite strong revenue growth, Harrow faces challenges with its ROE and ROA.
The increase in analyst price targets and the shift towards a bullish sentiment suggest a positive outlook for Harrow's stock in the short term. The company's strong revenue growth supports this optimism, although challenges with ROE and ROA may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100